AstraZeneca lung cancer drug Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC) in a first line setting has been granted the breakthrough therapy designation by the by the US Food and Drug Administration.
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the first-line treatment of non-small cell lung cancer (NSCLC). This designation is specifically for treating metastatic NSCLC patients who have tested positive for […]
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination with chemotherapy, as a first-line treatment option for patients with advanced lung cancer who have not previously been treated with other medicines. This approval marks a pivotal development in the battle against metastatic non-squamous non-small cell lung […]
Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions.
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority review by the U.S. Food and Drug Administration (FDA) for its expanded use in treating lung cancer. This priority review specifically targets its application as a first-line treatment for patients […]